Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung

7680686250017 CH-68625 Konzentrat
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
Spevigo 450 mg/7,5 ml (60 mg/ml) , Konzentrat zur Herstellung einer Infusionslösung
1 / 3
google

Article details

Package size
2
Selling units
2
Measure
Durchstechflasche(n)
Galenic form
Konzentrat
Galenic group
Tinkturen/Desinfektion

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Summary of Product Characteristics
Allemand
13/03/2026
Summary of Product Characteristics
Français
13/03/2026
Summary of Product Characteristics
Italien
13/03/2026

Detailed composition

Substance Quantity Type Category
spesolimabum
450.0 MG Substance Wirkstoff (Principe actif)
natrii acetas trihydricus
- Substance HNIDK
acidum aceticum glaciale
- Substance HNIDK
saccharum
386.0 MG Substance HBESI
arginini hydrochloridum
- Substance HNIDK
polysorbatum 20
- Substance HNIDK
aqua ad iniectabile
- Substance HNIDK
natrium
6.8 MG Substance HBESI

Reimbursement information

Public price
CHF 16349.85
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/01/2025

Authorization holder

Leo Pharmaceutical Products Sarath Ltd.

8302 Kloten

Authorization information

Swissmedic authorization number
68625
Drug name
Spevigo, Konzentrat zur Herstellung einer Infusionslösung
Galenic form
KOINF
ATC Code
L04AC22
Authorization status
B
Dispensing category
A
First authorization
09/08/2023
Authorization expiration date
21/10/2027
IT Number
07.15.0.
Domain
Human medicine
Field of application
Generalisierte pustulöse Psoriasis

Package details

Description (FR)
SPEVIGO conc perf 450 mg/7.5ml 2 flac 7.5 ml
Description (DE)
SPEVIGO Inf Konz 450 mg/7.5ml 2 Durchstf 7.5 ml
Market launch
09/08/2023
Narcotic (BTM)
No
Buy us a coffee Explore the data